Brought to you by 
Oculis closes CHF20mm Series B round; adds CHF15.5mm
10 Jan 2019
Executive Summary
Oculis raised CHF20mm ($20.3mm) through its Series B financing to new backers Bay City Capital, Novartis Venture Fund, and Pivotal bioVenture Partners and returning shareholders Brunnur Ventures and Silfurberg. The company will use the funds for ongoing development of its lead compound OC118, which is in Phase IIb for diabetic macular edema. Proceeds will also be used to develop OC118 for other indications and for development of additional candidates that incorporate the firm's solubilizing nanoparticle (SNP) technology. Representatives from Bay City Capital, Novartis Venture Fund, Pivotal bioVenture, and Brunnur Ventures will take board seats.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oculis closes CHF20mm Series B round; adds CHF15.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice